Results 161 to 170 of about 36,545 (280)

Use of Neuromuscular Blocking Agents in Elderly Patients: A Narrative Review in Geriatric Medicine. [PDF]

Int J Gen Med
Radkowski P, Szewczyk M, Dabdoub T, Murthy R, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Flexible organic frameworks sequester neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. [PDF]

Chem Sci, 2022
Wu Y, Liu YY, Liu HK, Yu SB, Lin F, Zhou W, Wang H, Zhang DW, Li ZT, Ma D.   +9 more
europepmc   +1 more source

Ivermectin Toxicity in Humans and Animals: Clinical Spectrum, Mechanisms, and Management

Journal of Applied Toxicology, Volume 46, Issue 6, Page 1856-1870, June 2026.
ABSTRACT Ivermectin is a widely used macrocyclic lactone with established efficacy against a broad range of parasitic infections in humans and animals and a long‐standing reputation for clinical safety. However, increasing evidence indicates that ivermectin can produce clinically relevant toxicity under specific conditions, particularly involving the ...
Serkan Yilmaz, Bayram Göktaş, İlker Ateş, Mustafa Çelik   +3 more
wiley   +1 more source

Age-Specific Pharmacology of Neuromuscular Blocking Agents: A Comprehensive Review. [PDF]

Med Sci Monit
Radkowski P, Kowalczyk K, Łęczycka A, Oniszczuk H, Grabarczyk Ł.   +4 more
europepmc   +1 more source

Provider variability in the intraoperative use of neuromuscular blocking agents: a retrospective multicentre cohort study. [PDF]

BMJ Open, 2021
Althoff FC, Xu X, Wachtendorf LJ, Shay D, Patrocinio M, Schaefer MS, Houle TT, Fassbender P, Eikermann M, Wongtangman K.   +9 more
europepmc   +1 more source

Deubiquitinase YOD1 Inhibition Suppresses DEX‐ and Denervation‐Induced Muscle Atrophy Through MAFbx Destabilization

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
ABSTRACT Backgrounds Muscle atrophy, characterized by progressive loss of muscle mass and function, is driven by muscle‐specific E3 ligases MAFbx and MuRF1. While transcriptional regulation of E3 ligases is documented, the mechanism of their regulation by the ubiquitin–proteasome system remains unclear. This study aims to identify a deubiquitinase (DUB)
Jongbeom Chae, Seon Min Woo, Seung Un Seo, Simmyung Yook, Hyo Je Cho, Jung Yeol Lee, Kyoung jin Min, Junhyeon Park, Dongryeol Ryu, Taeg Kyu Kwon   +9 more
wiley   +1 more source

Development of the neuromuscular junction and neuromuscular blocking agents in neonates, infants and children: A narrative review. [PDF]

Eur J Anaesthesiol
Saldien V, Veyckemans F, Hansen TG.
europepmc   +1 more source

Reducing the dose of neuromuscular blocking agents with adjuncts: a systematic review and meta-analysis. [PDF]

Br J Anaesth, 2021
Weber V, Abbott TEF, Ackland GL.
europepmc   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source

Pharmacological strategies to minimize or avoid neuromuscular blocking agents during general anesthesia: a comprehensive approach from airway management to surgical requirements. [PDF]

Front Pharmacol
Zhan FQ, Guo R.
europepmc   +1 more source